FarmaKology Newsletter - Issue #73
FarmaKology Newsletter - Issue #73
Today's Startup
REVOLUTION Medicines
REVOLUTION Medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. Our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms, and therapeutic approaches. We pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.
News
PrecisionLife and Cyclica sign strategic partnership combining leading data-driven biology and chemistry platforms to create a rapid innovation engine for drug discovery
PrecisionLife Ltd. (“PrecisionLife”), the leading combinatorial analytics company driving understanding of disease biology and patient stratification, and Cyclica Inc. (“Cyclica”), the partner of choice for data-driven drug discovery, announced that they have entered into a strategic partnership to co-market and offer their complementary computational platforms as an integrated drug discovery factory. The companies will initially collaborate on up to 30 pharma and biotechnology drug discovery programs over the next two years.
LianBio Partners With Landos to Commercialize Colitis, Crohn’s Drugs in China
Landos Biopharma based in Blacksburg, Va., partnered with Shanghai, China-based LianBio to develop and commercialize omilancor and NX-13 in Greater China and select Asian markets. Omilancor is an oral, gut-restrict LANCL2 agonist being developed for ulcerative colitis (UC), Crohn’s disease (CD), and Eosinophilic Esophagitis (EoE). NX-13 is an oral, gut-restricted compound targeting NLRX1 being developed for UC and CD.
Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial
The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who have recovered from COVID-19, in all adult age groups in a Phase 2 study with 722 volunteers. A global pivotal Phase 3 study is expected to start in the coming weeks.
Lilly signs pact with Natco to accelerate the availability of baricitinib for Covid-19 patients
Eli Lilly and Company said on Monday it has issued an additional royalty-free, non-exclusive voluntary license to Natco Pharma, a local pharmaceutical manufacturer of generic medicines. Natco will collaborate with Lilly to accelerate the availability of baricitinib in India and improve local treatment options for patients battling Covid-19 patients.
Research & Study
Scientists find a new way of predicting COVID-19 vaccine efficacy
Lipid droplets may prevent kidney damage from high-fat diets
Thrombosis can be prevented by prompt treatment
Podcast
Job Opportunities
Medical Representative
Pharmacy Technician
clinical pharmacist
Pharmacist
Upcoming Webinar
Realise the true power of your online, atline and offline biologics data
Turning the Toyota way into the pharma way to improve cost efficiency in the lab
Pharma Manufacturing Automation 2021
Video
